

BLOOD CANCER OXR – FINAL REPORT**Patient Information****Identification Data**

HRN: BRE00000273
Name: <PII> <PII>

Personal Data

Age (years): 23

Comorbidities

Atherosclerosis: No
Chronic Liver Disease: Yes
Diabetes Mellitus 1 or 2: No
Jaundice: No
Renal Failure: Yes

General Biochemistry

Creatinine (mg/dL): 1.00
ASAT (U/L): 8.00
ALAT (U/L): <PII>
GGT (U/L): 7.00
Total Bilirubin (mg/dL): 1.00
Hemolized Sample: No

Serum Tumor Markers

CA 15.3 (U/mL): 19.70
CEA (ng/mL): 1.60
EGFR (ng/mL): 5.00
NGAL (ng/mL): 4.60
NSE (ng/mL): 7.00

Blood Drawn Realization

Blood Drawn Date: <PII>

Urine Tumor Markers

<PII> (ng/mL): 11.10

Urine Drawn Realization

Urine Drawn Date: <PII>

Lifestyle

Smoking: Negative

Outcome**Results**

Some Tumor Markers are outside the reference range and suggest malignancy.

“High”

Range: Low, Moderate, High

Comments

In absence of comorbidities that are well-known source of False <PII> (FP) in healthy patients by increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.

Conclusions

WE SUGGEST BLOOD CANCER. THE <PII> ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT NEOPLASM OF BLOOD).

This report has been generated from the data entered on <PII> 10:55:02 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Blood Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial tumor.

The Royal <PII> Hospital,

<PII>

<PII> friendsrlh.com

Website: www.friendsoftheroyallondonhospital.<PII>



Technical Responsible

<PII> Lendinez

Chief Scientific Officer

The Royal <PII> Hospital